1. Home
  2. PROF vs TLSI Comparison

PROF vs TLSI Comparison

Compare PROF & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

N/A

Current Price

$7.05

Market Cap

230.4M

Sector

Health Care

ML Signal

N/A

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

N/A

Current Price

$5.33

Market Cap

272.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PROF
TLSI
Founded
N/A
2010
Country
Canada
United States
Employees
N/A
110
Industry
Medical/Dental Instruments
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
230.4M
272.3M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
PROF
TLSI
Price
$7.05
$5.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$12.00
$12.00
AVG Volume (30 Days)
148.8K
141.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.14
N/A
Revenue
$10,680,000.00
N/A
Revenue This Year
$61.09
$55.47
Revenue Next Year
$120.94
$40.05
P/E Ratio
$6.18
N/A
Revenue Growth
48.35
N/A
52 Week Low
$3.90
$3.42
52 Week High
$8.95
$7.95

Technical Indicators

Market Signals
Indicator
PROF
TLSI
Relative Strength Index (RSI) 51.38 54.27
Support Level $7.00 $4.90
Resistance Level $7.18 $5.61
Average True Range (ATR) 0.42 0.32
MACD 0.07 0.11
Stochastic Oscillator 98.29 87.18

Price Performance

Historical Comparison
PROF
TLSI

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Share on Social Networks: